focus -WSS

focus

author：comprehensive 2025-10-01 21:40:53 - browse：2

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： In diabetes hearing, Sanders takes on a new foe: food makers

knowledge

WSS

Leukemia patients are helped by Syndax's new type of therapy

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Stop Congress from blocking public access to science

CMS should re

focus

focus

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Chemotherapy shortages won’t get better under Biden’s latest plan

Cancer drug shortages should be causing more outrage

Medicare innovation center doesn’t save money, experts say

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Medical leaders decry Supreme Court decision on affirmative action

6 solutions to address cancer drug shortages and others

Peter Hotez and the public health issue of online harassment

Supreme Court wrestles with OxyContin maker's bankruptcy deal

hotspot

Stop Congress from blocking public access to science

What will Novo Nordisk's VC do with its influx of cash?

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Experts study whether long Covid risk adds up with each reinfection

CMS should re

CMS should re

Wikipedia

hotspot

knowledge

leisure time